Searched for: author%3A%22Koudstaal%2C+W.%22
(1 - 3 of 3)
Hartgroves, L.C.S. (author), Koudstaal, W. (author), McLeod, C. (author), Moncorgé, O. (author), Thompson, C.I. (author), Ellis, J. (author), Bull, C. (author), Havenga, M.J.E. (author), Goudsmit, J. (author), Barclay, W.S. (author), TNO Kwaliteit van Leven (author)
Most influenza vaccines are produced in chicken eggs but recent human influenza strains often do not grow well in this substrate. The PER.C6® cell line is an alternative platform for vaccine production. Here we demonstrate that PER.C6 cells faithfully propagate recent clinical isolates, without selecting for mutations in the HA gene. PER.C6...
article 2010
Koudstaal, W. (author), Hartgroves, L. (author), Havenga, M. (author), Legastelois, I. (author), Ophorst, C. (author), Siewerts, M. (author), Zuijdgeest, D. (author), Vogels, R. (author), Custers, J. (author), de Boer-Luijtze, E. (author), de Leeuw, O. (author), Cornelissen, L. (author), Goudsmit, J. (author), Barclay, W. (author), TNO Kwaliteit van Leven (author)
Reverse genetics, the generation of influenza viruses from cDNA, presents a rapid method for creating vaccine strains. The technique necessitates the use of cultured cells. Due to technical and regulatory requirements, the choice of cell lines for production of human influenza vaccines is limited. PER.C6® cells, among the most extensively...
article 2009
Vogels, R. (author), Zuijdgeest, D. (author), van Rijnsoever, R. (author), Hartkoorn, E. (author), Damen, I. (author), de Béthune, M.-P. (author), Kostense, S. (author), Penders, G. (author), Helmus, N. (author), Koudstaal, W. (author), Cecchini, M. (author), Wetterwald, A. (author), Sprangers, M. (author), Lemckert, A. (author), Ophorst, O. (author), Koel, B. (author), van Meerendonk, M. (author), Quax, P. (author), Panitti, L. (author), Grimbergen, J. (author), Bout, A. (author), Goudsmit, J. (author), Havenga, M. (author)
Replication-deficient human adenovirus type 5 (Ad5) can be produced to high titers in complementing cell lines, such as PER.C6, and is widely used as a vaccine and gene therapy vector. However, preexisting immunity against Ad5 hampers consistency of gene transfer, immunological responses, and vector-mediated toxicities. We report the...
article 2003